INFORMATION INTENDED FOR GLOBAL HEALTHCARE PROFESSIONALS

Information on Obtaining Sativex®

If you are a patient please note that we cannot provide advice on the suitability of Sativex® for individual patients. Patients wishing to know more about Sativex® should discuss with their doctor the most suitable treatment for them.

Please click on the link below to find out information within your territory:

In the UK, Sativex® is indicated as treatment for symptoms improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.

Sativex® is marketed in the UK by Bayer PLC (http://www.bayer.co.uk). If you are a medical professional and would like further information on Sativex® please contact Bayer PLC using the details below.

  • http://www.bayer.co.uk
  • Tel: +44 118 206 3119
  • Email: medical.information@bayer.co.uk

Adverse events should be reported.
To report an adverse event with Sativex®  click here.

Almirall S.A. is GW’s partner in Europe and therefore any enquiries relating to Sativex® from medical professionals in Europe should be directed to Almirall using their website.

Sativex® is approved in the following countries in mainland Europe: Switzerland, Norway and Turkey.

In all of these countries other than Switzerland the marketing authorization for Sativex® is held by GW Pharma. The marketing authorization for Sativex® in Switzerland is held by Almirall S.A.’s Swiss affiliate.

If you are a medical professional in Europe and would like further information on Sativex® please contact Almirall using the following link:

www.AlmirallMED.com

Almirall Med Screenshot

Bayer Canada is GW’s partner in Canada and therefore any enquiries relating to Sativex® from medical professionals in Canada should be directed to Bayer. If you are a medical professional in Canada and would like further information on Sativex® please contact Bayer Canada using the following information:

In Australia and New Zealand Sativex® has received marketing authorization and is indicated as treatment for symptoms improvement in patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.

Emerge Health Pty Ltd are the legally registered Sponsor for Sativex® in Australia and New Zealand and are currently working with local health authorities to enable supply of Sativex® in each country.  For information on its availability in Australia and New Zealand, please contact Emerge Health:

  • email: customerservice@emergehealth.com.au
  • telephone:  +61 (0)3 9077 4486,
  • In writing: Emerge Health Pty Ltd
    Suite 3, Level 1, 2 Theatre Place
    Canterbury VIC 3126,
    Australia

Neopharm Ltd is GW’s partner in Israel and therefore any enquiries relating to Sativex® from medical professionals in Israel should be directed to Neopharm.

Neopharm Medical Department Contact:
Medical Affairs Department

For Latin America GW Pharmaceuticals has partnered with Beaufour Ipsen Pharmaceuticals.

http://www.ipsen.com/

In Brazil Sativex® has received marketing authorization under the brand name of Mevatyl® and is indicated as treatment for symptoms improvement in patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.  

Contact for Brazil - Dr. Sandra Gonçalves - sandra.goncalves@ipsen.com

Sativex® has also received marketing authorization in Colombia and Chile for the same indication. 

Contact for Rest of Latin America - Dr. Margarita Nunez - margarita.nunez@ipsen.com

Sativex® is not currently approved for use in the United States of America.

Medical professionals in the USA wishing to obtain more information on Sativex®(nabiximols) should contact: medinfo.USA@greenwichbiosciences.com

 

Medical professionals wishing to obtain more information on Sativex® in countries where it is awaiting approval should contact IDIS Limited who specialize in the supply of unlicensed medicines:

 

IDIS Managed Access
MAPProgramAssociate@clinigengroup.com
www.clinigengroup.com

Summary of Product Characteristics